cyrilzakka/clinical-trials huggingface dataset:
Comparison of IV Ergonovine With IM Carboprost, With Oxytocin IV, During Cesarean Section for Failure to Progress

Patients having Cesarean section after they have been in labor for many hours bleed much more, in average twice as much, as compared with patients having an elective Cesarean section. The investigators believe a simple change in practice might contribute to reduce this bleeding. This study will involve the use of oxytocin (also known as syntocinon), ergonovine (also known as ergot) and carboprost (also known as hemabate). Oxytocin is routinely used to help contract the uterus and keep it contracted after the delivery of the baby and placenta, so as to reduce the amount of blood loss. Ergonovine is also given through the intravenous line, while carboprost is given as an injection in the muscle. Although they are not routinely given in every case, these are very frequently given as rescue medications to patients who fail to respond appropriately to oxytocin. This study is designed to determine if ergonovine or carboprost given in association with oxytocin, in a preventive way, after delivery of the baby and placenta, can reduce the amount of blood loss during Cesarean sections following a trial of labour.

The objective of the investigators study is to compare the efficacy of intravenous ergonovine and intramuscular carboprost, when administered with oxytocin infusion, prophylactically to decrease blood loss at Cesarean section for labor arrest. Desensitization of the oxytocin receptors has been recently demonstrated in cultured human myometrial cells after continuous and prolonged exposure to oxytocin in-vitro. This could be also the reason for a greater risk of uterine atony and postpartum hemorrhage (PPH) seen in women requiring induction and augmentation of labor. Therefore, addition of a different uterotonic agent, involving a different mechanism of action, to oxytocin infusion is likely to be beneficial, especially in women undergoing CS following failure to progress in labor, who are at a greater risk for PPH.

Eligibility Criteria:
Inclusion Criteria:

* patients who give written informed consent
* patients undergoing Cesarean section for failure to progress in labour, under regional anesthesia
* patients should be in the first stage of labour and have received oxytocin for at least 4 hours

Exclusion Criteria:

* patients who refuse to give written informed consent
* patients who require general anesthesia
* patients who claim allergy or hypersensitivity to oxytocin, ergot derivatives or prostaglandins
* patients with cardiac diseases and hypertension or preeclampsia ( diastolic blood pressure \> 90 mmHg, systolic blood pressure \> 140 mmHg )
* patients with asthma or any other respiratory disease
* patients with conditions at risk of PPH such as placenta previa, multiple gestation, preeclampsia, macrosomia, polyhydramnios, uterine fibroids, previous history of uterine atony and postpartum bleeding, bleeding diathesis and known infection.
Evaluation of Topical Lidocaine Spray as Adjuvant to Upper Gastrointestinal Endoscopy in Children

There is some controversy in the medical literature regarding the effectiveness of topical lidocaine in children as an adjuvant drug to upper gastrointestinal endoscopy. In children, deep sedation and general anesthesia are often used to sedate children submitting to this procedure. Propofol is an anesthetic drug increasingly popular in this situation, but this drug can only be used with an anesthesiologist in Brazil. Its main side effects include hypotension, respiratory depression and local pain. Lidocaine is frequently used as premedication, and the rationale is that lowering patient discomfort could lower the required dose to achieve the endoscopy and reduce potential side effects. Nevertheless, some patients perceive this medication as uncomfortable. This study aims to compare sedative drug doses between patients who were given either placebo or topical lidocaine.

This study is a randomized double-blind placebo-controlled clinical trial.

Primary outcome: propofol doses required to achieve adequate sedation.

Population: children submitting to upper digestive endoscopy, weight \> 30 kg and age between 8 and 18 years.

Exclusion criteria: neurological disorders, psychiatric disorders, specific contra-indication to either lidocaine or propofol.

Estimated sample: 160 patients. Placebo: tannic acid 0.5%

Eligibility Criteria:
Inclusion Criteria:

* Children and adolescents submitting to upper digestive endoscopy with weight above 30 kg and age between 8 and 18 years

Exclusion Criteria:

* Neurological disorders
* Psychiatric disorders
* Specific contra-indication to lidocaine
* Specific contra-indication to propofol
Ultrasonographic Assessment of Lung Recruitment Maneuvers in Children Undergoing Lengthy Microsurgery Operations

The aim of this study will be to explore the clinical value of ultrasonic monitoring in the diagnosis of anesthesia-induced atelectasis, the assessment of the effects of lung recruitment, the best positive end-expiratory pressure (PEEP) after RM and in the detection of the point of lung re-collapse after RM in pediatric patients undergoing lengthy microsurgery operations using two levels of intraoperative FIO2 (0.5 VERSUS 0.3).

* To maximize the benefits, minimize the drawbacks and assess the adequacy of the recruitment maneuver; adequate monitoring at the bedside is essential. Several methods have been proposed, including measuring end-expiratory lung volume or pulmonary compliance, volumetric capnography, oxygenation indices, electrical impedance tomography, computerized tomography and lung ultrasound.
* For lung CT examination patients must be transported out to the radiation unit, which carries risk of transfer, high cost, and radiation exposure. The oxygenation method which is the most commonly used, but it is necessary to repeat arterial blood collection many times, which is cumbersome and expensive.
* Using lung ultrasound (LUS) as real-time guidance during the recruitment maneuver has gained popularity recently owing to its' easy applicability and non-invasive nature. Sonography is a radiation-free methodology which plays an important role in diagnosing pulmonary diseases in children, including obstructive and compressive atelectasis of different origins. Furthermore, lung ultrasound has shown reliable sensitivity and specificity for the diagnosis of anaesthesia-induced atelectasis in children.
* LUS can identify children needing a recruitment maneuver to re-expand their lungs and help optimize ventilator treatment during anesthesia.

Eligibility Criteria:
Inclusion Criteria:

* Age: 2-12 years old.
* ASA physical status classification I-II.
* Undergoing lengthy microsurgery operations
* and requiring endotracheal intubation and mechanical ventilation for more than 4 hours.-

Exclusion Criteria:

* ASA Physical status classification \>II.

  * Thoracic or abdominal surgery.
  * Preexisting lung disease.
  * Pre-operative chest infection or abnormal chest US findings.
  * Cardiac patients.-
An Observational Study of First-Line Bevacizumab (Avastin) With Fluoropyrimidine-Based Chemotherapy in Participants With Metastatic Colorectal Cancer

This multicenter observational study will evaluate the efficacy and safety of first-line bevacizumab (Avastin) in combination with fluoropyrimidine-based chemotherapy in participants with metastatic colorectal cancer (mCRC). Participants for whom the treating physician has decided to initiate first-line fluoropyrimidine based chemotherapy in combination with bevacizumab will be observed for approximately 4 years.


Eligibility Criteria:
Inclusion Criteria:

* Participants with histologically confirmed metastatic colorectal cancer who will receive bevacizumab in combination with first-line fluoropyrimidine-based chemotherapy

Exclusion Criteria:

* Participants not qualified for bevacizumab treatment according to the local label
An Analysis in the Use of Telecommunication Platform

The COVID-19 pandemic becomes a global challenge. Beneficial to being an island country and having appropriate policies, there were only few imported cases in Taiwan. However, many locally acquired cases came out in the mid of this May. The hospital policy about containing infection changed accordingly.

A real-time communication platform for the health care workers was designed and embedded in the hospital information system of the emergency department in 2018. The functions included sending messages to certain staff, pop-up reminders, and tracking messages. This study aims to evaluate the use of the communication platform during the COVID pandemic.

The COVID-19 pandemic becomes a global challenge. Beneficial to being an island country and having appropriate policies, there were only few imported cases in Taiwan. However, many locally acquired cases came out in the mid of this May. The hospital policy about containing infection changed accordingly.

A real-time communication platform for the health care workers was designed and embedded in the hospital information system of the emergency department in 2018. The functions included sending messages to certain staff, pop-up reminders, and tracking messages. This study aims to evaluate the use of the communication platform during the COVID pandemic.

Eligibility Criteria:
Inclusion Criteria:

healthcare workers with using the communication platform.

Exclusion Criteria:

healthcare workers without using the communication platform.
A Survey of Physician and Molecular Tumor Board Perspectives on the Clinical Utility and Usability of Cellworks Singula™ and Ventura™ Reports in Facilitating Patient Treatment Decisions for Pan-Cancer Patients

The purpose of this study is to determine the benefit of Cellworks Singula™ and Ventura™ reports on physician and molecular tumor board treatment recommendations across a large set of pan-cancer indications. Cellworks reports aim to provide NGS-based therapy recommendations to aid the decision-making of patients, physicians, and molecular tumor boards.


Eligibility Criteria:
1. Have any stage of cancer for the indications listed at: https://cellworks.life/mycare101 Patients are eligible at any stage of disease.
2. Expected to be alive 6 months or more
3. Requirements for NGS testing (e.g., panel or whole-exome sequencing): NGS testing has been ordered from or performed by one or more vendors specified at: https://cellworks.life/mycare101 . NGS reports must be ordered or performed within the last 90 days. Cellworks will accept all NGS input formats available, including PDF, VCF, BAM, and FastQ.
4. Requirements for additional laboratory testing If Hematological Indication, Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered If Acute Myeloid Leukemia (AML), FLT3-itd testing has been ordered If Indication is a form of Brain Cancer (e.g., glioblastoma), Cytogenetics in the form of FISH, Karyotyping, IHC, and/or aCGH has been ordered and MGMT Methylation test has been ordered
Relationship Between Chronic Non-Specific Neck Pain And Lumbar Reposition Sense

to investigate the correlation between chronic non-specific neck pain and lumbar reposition sense.

Around 67% of people on the planet may at some point in their lives experience chronic, non-specific neck pain. People who have chronic pain frequently need medical services and medications for pain treatment, and there is a link between their functional limitations and disabilities.

Cervical pain without a recognized clinical reason for the complaints is classified as chronic non-specific neck pain. Some symptoms include weakening in the neck muscles and reduced mobility of the cervical spine.

"Pain perceived anywhere in the posterior region of the cervical spine, from the superior nuchal line to the first thoracic spinous process" is how the International Association for the Study of Pain (IASP) characterized chronic non-specific neck pain.

Individuals who experience unilateral or central neck discomfort are said to have persistent non-specific neck pain. There will be restricted range of motion in the neck, which frequently re-creates the symptoms; referred shoulder girdle or upper extremity pain may also be felt. Patients may also get cervicogenic headaches (CGH).

Spine position, stability, and movement are all governed by motor control, which results from the ongoing interaction of sensory inputs, such as proprioception, on different neural system levels, and motor outputs to effectors, such as paraspinal muscles.

The capacity to precisely position the trunk at predefined points along the sagittal plane's range of motion is known as trunk position sense. Trunk repositioning protocols may be a valuable tool for measuring trunk control since they demand that participants precisely move and control the flexing trunk.

The most popular criterion for assessing proprioceptive senses is joint repositioning errors. By first generating a target angle or joint location using position or movement sensors, then having the subject represent that place, the test examines the discrepancy between the initial target location and the location realised by the subject.

Eligibility Criteria:
Inclusion Criteria:

1. Male and female patients,18-50 years old
2. Neck pain continued for at least the last 12 weeks
3. Normal Body mass index ranged from 18.5 to 24.9

Exclusion Criteria:

1. Radiated neck pain
2. Neck pain associated with vertigo
3. A history of surgery on the lower limbs or back
4. Back or lower extremity trauma within the last three months.
5. neurological or vestibular disorders
6. Diagnosed psychological disorders
7. Vertebral fractures
8. Metal spine implants
9. Tumors
10. Diagnosed metabolic diseases
11. Using medications that could have an impact on balance in the 24 hours before to the study
12. Previous neck surgery
13. Red flags (night pain, severe muscle spasms, sudden loss of weight)
14. Physiotherapeutic treatment continued in the last 3 months
15. Pregnancy, including six months postpartum
16. A diagnosed psychiatric disorder or severe cognitive impairment
Blood Flow-restricted Resistance Exercise to Promote Muscle Strength and Use in Adults With Incomplete Spinal Cord Injury

Recovery of arm and hand motor control is critical for independence and quality of life following incomplete spinal cord injury (iSCI). Blood flow-restricted resistance exercise (BFRE) has emerged as a potential treatment addressing this need, but treatment guidelines and research reporting effectiveness are sparse. The purpose of this work is to provide case reports of people with cervical iSCI who use BFRE supplemented by electrical stimulation (ES) to increase the strength and functional use of selected upper extremity muscles.


Eligibility Criteria:
Inclusion Criteria:

* Incomplete cervical spinal cord injury
* Resting blood pressure between 80/50 mmHg and 150/90 mmHg for at least three consecutive days
* Native speaker of English

Exclusion Criteria:

* Recent history of deep vein thrombosis or cardiovascular disease including uncontrolled hypertension or a blood-clotting disorder
* Routine experience of orthostatic hypotension as defined as a drop in systolic/diastolic blood pressure greater than 20/10 mmHg when engaging in physical activity
* Severe cognitive, communication, or behavioral disorder as determined by treatment team
Calcium Folinate Treatment of Spastic Paraplegia 56

SPG56 is one of the complicated and early-onset HSP subtypes caused by genetic mutations in CYP2U1. So far, there is no standardized and specific clinical therapy for SPG56. The goal of this clinical trial is to explore the efficacy and safety of calcium folinate in the treatment of SPG56 patients.

This study is prospective, open-label and single arm and this trial will last for 6 years. A total of 10 patients will participate and they will receive calcium folinate treatment and professional clinical evaluation regularly.


Eligibility Criteria:
Inclusion Criteria:

1. Patients meet the clinical diagnostic standard of hereditary spastic paraplegia (HSP);
2. Spastic paraplegia type 56 (SPG56) was diagnosed by CYP2U1 pathogenic mutation;
3. Patients are willing to participate in clinical trials and able to understand and comply with the research program.

Exclusion Criteria:

1. Patients are allergic to the drugs involved in the study;
2. Other neurological diseases likely affecting the evaluation of study treatment;
3. Other medical conditions such as: heart disease, tumor, blood disease, liver disease, kidney disease, etc. in the past 1 year;
4. Pregnancy or lactating women or subjects who are unable to use appropriate contraception during the trial;
5. Participating in another study drug trial and used the investigational drug in the past 30 days;
6. Subjects have poor compliance or other factors that are not suitable for participating in the clinical trial.
Clinical Study of Acupuncture in the Treatment of Diabetic Peripheral Neuropathy

Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes mellitus that has a considerable impact on quality of life, but there are few effective therapeutic strategies. The aim of this trial is to determine the efficacy and safety of manual acupuncture (MA) versus sham acupuncture (SA) for DPN.

A total of 118 patients with DPN will be recruited and randomly assigned in a 1:1 ratio to either the MA group or SA group. All patients will receive 24 sessions over 12 weeks. Participants will complete the trial by visiting the research center at month 6 for a follow-up assessment. The primary outcome is peroneal motor nerve conduction velocity (peroneal MNCV) at week 12 compared with baseline. Secondary outcomes include peroneal motor nerve action potential amplitude (peroneal MNAP) and latent period (peroneal MNLP), sural sensory nerve conduction velocity (sural SNCV), action potential amplitude (sural SNAP) and latent period (sural SNLP), fasting plasma glucose (FPG), 2-h postprandial blood glucose (2hPG), glycated hemoglobin (HbAlc) at week 12 compared with baseline, Michigan Neuropathy Screening Instrument (MNSI) score and Diabetes Specific Quality of Life scale (DSQL) at week 12 and month 6 compared with baseline. Safety will be assessed during the whole trial. Masking effectiveness will be assessed by patients.

Eligibility Criteria:
Inclusion Criteria:

* 1. Aged 18-75 years (either sex)
* Patients who meet diagnosis of DPN defined by ADA in 2005：a. DPN is defined as the presence of symptoms and/or signs of peripheral nerve dysfunction in people with diabetes, after the exclusion of other causes. b. NP is defined as altered sensitivity to pressure and (1) altered sensitivity to pain or (2) altered sensitivity to vibration or (3) achilles reflex.
* Symmetric and predominantly sensory, starting from the lower limbs distally and gradually spreading proximally in a glove-and-stocking distribution.
* Ability to understand study procedures and willingness to comply with them for the entire period of study.
* Written informed consent

Exclusion Criteria:

* PN caused by conditions other than diabetes (e.g.,alcohol abuse, chemotherapy, hereditary causes, chronic inflammatory, or idiopathic PN)
* Psychiatric illnesses other than mild depression.
* Severe or unstable cardiovascular, liver, kidney, respiratory, or hematological disorders.
* Received acupuncture treatment in the last 3 months.
* Pregnant or lactating women.
* Research unit personnel directly related to the study and their immediate family members.
* Incapable of giving informed consent or following the study instructions due to language disturbances, serious cognitive deficits, or lack of time.
* Currently participating in other clinical trials.
Clinical Evaluation of Compomer and Composite Class II Restorations in Primary Molars: 24 Months Results

It was aimed to evaluate the clinical performance of resin-hybrid composite and compomer materials in primary molars over a 2-year period.

All treatment stages were performed by the same experienced pediatric dentist (E.O.) to avoid behavioral problems. When necessary, topical anesthesia with 2% Xylocaine® DENTAL was administered, followed by local anesthesia with epinephrine 1: 100.000 (lidocaine HCl and Epinephrine Injection, DENTSPLY Pharmaceutical, USA). Access to proximal surfaces was provided with high-speed diamond bur (FD.D.801, Frank Dental, Germany) under an air-water coolant. The proximal cavity was opened at the occlusal level. Soft carious dentine was removed with a round low-speed steel bur (SS.1A, Frank Dental, Germany).

Restorations were placed under isolation with cotton rolls and a saliva ejector. The Ca(OH)2 cavity liner material (Hydrocal LC, Medicept Dental, India) was used as base material if the distance from the pulp was not safe. A metal matrix band (Matrix band, Hahnenkratt, Königsbach-Stein, Germany) was applied to the tooth with a universal matrix system (Tofflemire, Hahnenkratt, Königsbach-Stein, Germany) and wooden wedges (TDV, No 1). ClearfilTM SE Bond (Kuraray Medical Inc, Okayama, Japan) was applied to the cavity according to the manufacturer's instructions. For the polymerization, an LED curing light (Eliapar Freelight, 3M ESPE Dental Products, America) was used with a light power density of 600 mW/cm2. According to the manufacturer's instructions, A2 composite resin (Kerr Herculite Classic) and two different compomer materials (Dyract/XP and R\&D Series NOVA) were applied to the teeth with the incremental technique, and each increment was light-polymerized for 20 sec with an LED curing light.

Eligibility Criteria:
Inclusion Criteria:

\* Mentally and physically healthy

Exclusion Criteria:

\* Systemic disease or medical complications